BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide

Cancer Immunology, Immunotherapy

Volumn 62, Issue 6, 2013, Pages 983-987

  Sanchez Perez, Luis ^a   Choi, Bryan D ^a   Reap, Elizabeth A ^a   Sayour, Elias J ^a   Norberg, Pamela ^a   Schmittling, Robert J ^a   Archer, Gerald E ^a   Herndon II, James E ^a   Mitchell, Duane A ^a   Heimberger, Amy B ^b   Bigner, Darell D ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BAFF; BLyS; Immunotherapy; Lymphopenia; Temozolomide; Vaccines

Indexed keywords

B CELL ACTIVATING FACTOR; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; PEPTIDE VACCINE; TEMOZOLOMIDE;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; B CELL ACTIVATING FACTOR BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANTIBODIES; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS, ALKYLATING; B-CELL ACTIVATING FACTOR; CANCER VACCINES; DACARBAZINE; GLIOBLASTOMA; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOPENIA;

EID: 84878892458     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1405-y     Document Type: Article

References (25)

1. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. J Exp Med 202(7):907-912. doi: 10.1084/jem.20050732
2. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6(5):383-393. doi: 10.1038/nri1842
3. Cancro MP (2004) The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 202:237-249. doi: 10.1111/j.0105-2896.2004.00212.x
4. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML (2003) Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 198(6):937-945. doi: 10.1084/jem.20030789
5. Woodland RT, Schmidt MR, Thompson CB (2006) BLyS and B cell homeostasis. Semin Immunol 18(5):318-326. doi: 10.1016/j.smim.2006.06.001
6. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35(7):1256-1264. doi: 08/13/061
7. Gor DO, Ding X, Li Q, Sultana D, Mambula SS, Bram RJ, Greenspan NS (2011) Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS). Biol Direct 6:9. doi: 10.1186/1745-6150-6-9
8. Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, Karlsson MC, Mascola JR, Wyatt RT, Cancro MP, Karlsson Hedestam GB (2012) BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol 188(12):6018-6026. doi: 10.4049/jimmunol.1200466
9. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491-502. doi: 10.1038/nri2572
10. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2(7):465-475. doi: 10.1038/nri844
11. Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, Tamassia N, Pieropan S, Biasi D, Sbarbati A, Sozzani S, Bambara L, Cassatella MA (2005) Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 105(2):830-837. doi: 10.1182/blood-2004-02-0564
12. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C, Cassatella MA (2003) G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 197(3):297-302
13. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, Plebani A, Lougaris V, Quinti I, Thon V, Litzman J, Schlesier M, Warnatz K, Thiel J, Rolink AG, Eibel H (2012) Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 188(1):497-503. doi: 10.4049/jimmunol.1102321
14. Schneider P, Tschopp J (2003) BAFF and the regulation of B cell survival. Immunol Lett 88(1):57-62
15. Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP (2005) Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin Immunol 17(3):193-199. doi: 10.1016/j.smim.2005.02.001
16. Waldschmidt TJ, Noelle RJ (2001) Immunology. Long live the mature B cell-a baffling mystery resolved. Science 293(5537):2012-2013. doi: 10.1126/science.1065591
17. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML (2001) An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293(5537):2111-2114. doi: 10.1126/science.1061964
18. Cassani B, Poliani PL, Marrella V, Schena F, Sauer AV, Ravanini M, Strina D, Busse CE, Regenass S, Wardemann H, Martini A, Facchetti F, van der Burg M, Rolink AG, Vezzoni P, Grassi F, Traggiai E, Villa A (2010) Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med 207(7):1525-1540. doi: 10.1084/jem.20091928
19. Walter JE, Rucci F, Patrizi L, Recher M, Regenass S, Paganini T, Keszei M, Pessach I, Lang PA, Poliani PL, Giliani S, Al-Herz W, Cowan MJ, Puck JM, Bleesing J, Niehues T, Schuetz C, Malech H, DeRavin SS, Facchetti F, Gennery AR, Andersson E, Kamani NR, Sekiguchi J, Alenezi HM, Chinen J, Dbaibo G, ElGhazali G, Fontana A, Pasic S, Detre C, Terhorst C, Alt FW, Notarangelo LD (2010) Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J Exp Med 207(7):1541-1554. doi: 10.1084/jem.20091927
20. Crowley JE, Scholz JL, Quinn WJ III, Stadanlick JE, Treml JF, Treml LS, Hao Y, Goenka R, O'Neill PJ, Matthews AH, Parsons RF, Cancro MP (2008) Homeostatic control of B lymphocyte subsets. Immunol Res 42(1-3):75-83. doi: 10.1007/s12026-008-8036-y
21. Treml LS, Crowley JE, Cancro MP (2006) BLyS receptor signatures resolve homeostatically independent compartments among naive and antigen-experienced B cells. Semin Immunol 18(5):297-304. doi: 10.1016/j.smim.2006.07.001
22. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13(3):324-333. doi: 10.1093/neuonc/noq157
23. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28(31):4722-4729. doi: 10.1200/JCO.2010.28.6963
24. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE II, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8(10):2773-2779. doi: 10.1158/1535-7163.MCT-09-0124
25. Neyns B, Tosoni A, Hwu WJ, Reardon DA (2010) Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 116(12):2868-2877. doi: 10.1002/cncr.25035